Elderly patients are presenting themselves for advanced critical care services in ever-increasing numbers due to changing population demographics coupled with advances in medical technology and pharmacology. Medical management of the elderly in critical care settings is complicated by pre-existing multisystem chronic disease, polypharmacy, and age-related changes in pharmacokinetics and pharmacodynamics. Three principles in the management of the elderly in an intensive care unit (ICU) setting are discussed: (1) the protection of renal function from common nephrotic drugs; (2) the necessity of altered drug dosing due to changes in pharmacokinetics and pharmacodynamics; and (3) the necessity of avoiding polypharmacy. Strategies for the prevention of acute renal failure in ICU contrast studies are described. A review of pharmacodynamics and pharmacokinetics in the elderly is presented with examples of commonly seen ICU medication problems.
Get full access to this article
View all access options for this article.
References
1.
Statistical Abstract of the United States, U.S. Department of Commerce, Economics and Statistical Administration Bureau of the Census. 1992:18–19.
2.
United States Renal Data System.Annual Data Report. Am J Kidney Dis1991;18: 1–27.
3.
BeardK.Adverse reactions as a cause of hospital admission in the aged. Drugs Aging1992;2: 356–367.
HarrisonDC.Cost containment in medicine: why cardiology?Am J Cardiol1985;56: 10c–15c.
6.
BernsJSRudnickMR.Radiocontrast media associated nephrotoxicity. In: HumesHD, ed. The kidney, vol 24. New York: The National Kidney Foundation, 1992:1–6.
7.
CongerJDAndersonRJ.Acute renal failure including cortical necrosis. In: MassrySGGlassockRJ, eds. Textbook of nephrology, ed 2. Baltimore: Williams & Wilkins, 1989:865–880.
8.
BersethROKjellstrandCM.Radiologic contrast induced nephropathy. Med Clin North Am1984;68: 351–370.
9.
KatzbergRWMorrisTWBurgenerFARenal renin and hemodynamic responses to selective renal artery catheterization and angiography. Invest Radiol1977;12: 381–388.
10.
BrezisMRosenSEpsteinFH.Acute renal failure. In: BrennerBMRectorFC, eds. The kidney, ed 3. Philadelphia: W. B. Saunders, 1986:735–799.
St. John HammondPGCutlerRE.Dopamine, dopaminergic agents, and the kidney. Part I: pharmacology, vascular and tubular effects. Dialysis Transplant1989;18: 36–39.
13.
HansBHansSSMittalVKRenal functional response to dopamine during and after arteriography in patients with chronic renal failure. Radiology1990;176: 651–654.
14.
HallKAWonaRWHunterGCContrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res1992;53: 317–320.
15.
LindnerACulterREGoodmanWG.Synergism of dopamine plus fuorsemide in preventing acute renal failure in the dog. Kidney Int1979;16: 158–166.
16.
RudyDWVoelkerJRGreenePKLooop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than Babes therapy. Ann Intern Med1991;115: 360–366.
17.
van MeyelJJSmitsPRusselFGDiuretic efficacy of furosemide during continuous administration vs. bolus injection in healthy volunteers. Clin Pharmacol Ther1992;51: 440–444.
18.
MooreRDSteinbergEPPoweNRNephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology1992;182: 649–655.
19.
Boras-UberLABrackeettNCJr.Ketorolac-induced acute renal failure. Am J Med1992;92: 450–452.
20.
YuenGJ.Altered pharmacokinetics in the elderly. Clin Geriatr Med1990;6: 257–267.
21.
CrooksJO'MalleyKStevensonIH.Pharmacokinetics in the elderly. Clin Pharmacokinet1976;1: 280–296.
22.
WallaceSMVerbeekRK.Plasma protein binding of drugs in the elderly. Clin Pharmacokinet1987;12: 41–72.
23.
RossmanI.Clinical geriatrics, ed 3. Philadelphia: Lippincott, 1986:14–17.
24.
KaplanCPasternackBShahHAge related incidence of sclerotic glomeruli in human kidneys. Am J Pathol1975;80: 227–234.
25.
RoweJWAndresRTobinJDThe effect of age on creatinine clearance in men:a cross-sectional study. J Gerontol1976;31: 155–163.
26.
CockroftDWGaultMN.Prediction of creatinine clearance from serum creatinine. Nephron1976;16: 31–41.
27.
CusakBKellyJGLavanJPharmacokinetics of lidocaine in the elderly. Br J Clin Pharmacol1980;9: 293–294.
WallinJD.Intravenous nicardipine hydrochloride: treatment of patients with severe hypertension. Am Heart J1990;119: 434–437.
31.
SchultzV.Clinical pharmacokinetics of nitroprusside, cyanide, thiosulfate and thiocyanate. Clin Pharmacokinet1984;9: 239–251.
32.
RodenDM.Treatment of cardiovascular disorders: arrhythmias. In MelmonKLMorrelliHHoffmanBBNierenbergDW, eds. Clinical pharmacology: basic principles in therapeutics, ed 3. New York: McGraw-Hill, 1992:151–185.
33.
AllonMShaklinN.Adrenergic modulation of extrarenal potassium deposition in men with end stage renal disease. Kidney Int1991;40: 1103–1109.
34.
KaikoRFFoleyKMGrabinskiPYCentral nervous system excitatory effects of meperidine in cancer patients. Ann Neurol1983;13: 180–185.
35.
ChanGLCMatzkeGR.Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Dr Intell Clin Pharm1987;21: 773–783.
36.
SchorJDLevkoffSELipsitzCARisk factors for delerium in hospitalized elderly. J Am Med Assoc1992;267: 827–831.
37.
DeSoiCAUmansJG.Principles of drug therapy in renal failure. Hospital Formulary1992;27: 164–1180.
38.
ScottGNierenbergGS.Pharmacokinetics data for commonly used drugs. In: MelmonKLMorerelliHFHoffmanBBNierenbergsDW, eds. Clinical pharmacology: basic principles in therapeutics, ed 3. New York: McGraw-Hill, 1992:1029–1058.
